Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility

Scientific Reports
Chien-Chang YangChih-Jung Chen

Abstract

Bacteremia caused by MRSA with reduced vancomycin susceptibility (MRSA-RVS) frequently resulted in treatment failure and mortality. The relation of bacterial factors and unfavorable outcomes remains controversial. We retrospectively reviewed clinical data of patients with bacteremia caused by MRSA with vancomycin MIC = 2 mg/L from 2009 to 2012. The significance of bacterial genotypes, agr function and heterogeneous vancomycin-intermediate S. aureus (hIVSA) phenotype in predicting outcomes were determined after clinical covariates adjustment with multivariate analysis. A total of 147 patients with mean age of 63.5 (±18.1) years were included. Seventy-nine (53.7%) patients failed treatment. Forty-seven (31.9%) patients died within 30 days of onset of MRSA bacteremia. The Charlson index, Pitt bacteremia score and definitive antibiotic regimen were independent factors significantly associated with either treatment failure or mortality. The hVISA phenotype was a potential risk factor predicting treatment failure (adjusted odds ratio 2.420, 95% confidence interval 0.946-6.191, P = 0.0652). No bacterial factors were significantly associated with 30-day mortality. In conclusion, the comorbidities, disease severity and antibiotic regime...Continue Reading

References

Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Jan 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrick G P CharlesM Lindsay Grayson
May 20, 2008·International Journal of Antimicrobial Agents·Ian M Gould
Aug 1, 2008·Microbiology·Katrina E TraberRichard P Novick
Jan 13, 2009·The Journal of Antimicrobial Chemotherapy·Steven N LeonardMichael J Rybak
Apr 24, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R K C FongA Kurup
Nov 17, 2010·Antimicrobial Agents and Chemotherapy·Sebastiaan J van Hal, David L Paterson
Jan 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuUNKNOWN Infectious Diseases Society of America
Feb 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S J van HalD L Paterson
May 11, 2012·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yen-Cheng YehJung-Chung Lin
Mar 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kyle P MurrayMichael J Rybak

❮ Previous
Next ❯

Citations

Jan 30, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Aneta KaczorJadwiga Handzlik
Jun 21, 2019·Paediatric Drugs·Kannan SridharanHusain Am Al Ajooz
Jul 7, 2019·International Journal of Antimicrobial Agents·Arianna PaniFrancesco Scaglione

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SAS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.